Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Healthy male volunteers 18 to 45 years of age~* Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)~* Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m\^2)~* Part 1: Normal, intact skin without tattoos or lesions in the injection area~* Part 2: Females at least 18 years of age~* Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0~* Part 2: Previously treated, non-metastatic carcinoma of the breast~* Part 2: Baseline LVEF at least 55%~* Part 2: Negative pregnancy test and use of adequate contraceptive measures among women of childbearing potential~Exclusion Criteria:~* Part 1: Positive urine test for drugs of abuse~* Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Part 1: Cardiac disease including hypertension or hypotension~* Part 1: Lower extremity edema~* Part 1: Any clinically relevant history of systemic disease~* Part 1: History of breast cancer~* Part 1: Chronic corticosteroid use~* Part 1: Receipt of IV antibiotics within 7 days prior to enrollment~* Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening~* Part 2: Significant cumulative exposure to anthracyclines~* Part 2: Serious cardiac disease including uncontrolled hypertension~* Part 2: Poor hematologic, renal, or hepatic function~* Part 2: Pregnant or lactating women~* Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV~* Part 2: Chronic corticosteroid use~* Part 2: Receipt of IV antibiotics within 7 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV (Type: ACTIVE_COMPARATOR): Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
- Part 1-Cohort 2: Pertuzumab 400 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
- Part 1-Cohort 3: Pertuzumab 600 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
- Part 1-Cohort 4: Pertuzumab 1200 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
- Part 1-Cohort 5: Trastuzumab 600 mg SC (Type: ACTIVE_COMPARATOR): Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
- Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
- Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
- Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC (Type: EXPERIMENTAL): Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
- Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC (Type: EXPERIMENTAL): Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
- Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC (Type: EXPERIMENTAL): Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
- Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC (Type: EXPERIMENTAL): Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete